Rapport Therapeutics Reports Second Quarter Financials and Provides Business Update
Rapport Therapeutics, Inc. (RAPP)
Company Research
Source: GlobeNewswire
Completed initial public offering, raising $174.4 million in gross proceeds, including full exercise of the underwriters’ option to purchase additional shares and a concurrent private placement, to fund clinical development of precision neuroscience pipelinePhase 2a trial of RAP-219 in focal epilepsy initiation on track, with topline data expected in mid-2025 On track to begin two additional proof of concept clinical trials of RAP-219 in patients with peripheral neuropathic pain in 2H 2024, and patients with bipolar disorder in 2025Terry-Ann Burrell, who was recently appointed as vice chairman of investment banking at JPMorgan, will transition off the Board of Directors of Rapport following the Company’s Form 10-Q filingEnded the quarter with $336.1 million in cash, cash equivalents, and short-term investments, excluding restricted cash, which is expected to fund operations through the end of 2026 BOSTON, Mass. and SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeuti
Show less
Read more
Impact Snapshot
Event Time:
RAPP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RAPP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RAPP alerts
High impacting Rapport Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RAPP
News
- Rapport Therapeutics to Present at Upcoming Epilepsy Medical ConferencesGlobeNewswire
- Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry SummitGlobeNewswire
- Rapport Therapeutics to Present Data for TARP?8 AMPAR Negative Modulator at IASP 2024 World Congress on PainGlobeNewswire
- Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- Rapport Therapeutics (NASDAQ: RAPP) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $35.00 price target on the stock.MarketBeat